-
-
-
-
-
-
-
Sarepta Therapeutics' (SRPT) EMBARK Study Did Not Meet Primary Endpoint but Data Shows Robust, Statistically Significant Results
-
-
-
-
-
-
-
Sarepta (SRPT) tumbles 15% on 9001 decision delay; Analyst sees a buying opportunity
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) Reports Positive FDA AdCom Vote for SRP-9001
-
-
-
-
-
-
-
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
-
-
-
-
-
-
-
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
-
-
-
-
-
-
-
Sarepta Therapeutics (SRPT) Said FDA Accepted Casimersen (SRP-4045) NDA for Duchenne Muscular Dystrophy, Granted Priority Review Status
-
-
-
-
-
-
-
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application
-
13,042 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All